The role of palbociclib on the alterations in CDKN2, CCNE1, E2F3, MDM2 expressions as target genes of miR-141

Sep 22, 2026

Upload by Asher

Breast cancer is a major cause of cancer-related mortality worldwide, with cell-cycle dysregulation contributing to tumor development. Palbociclib, a selective CDK4/6 inhibitor used for ER+ metastatic disease, is investigated here for its impact on breast cancer cells and on gene expression changes linked to miR-141. MCF7 and MDA-MB-231 cells were treated with palbociclib at IC50-based doses for 24 and 72 hours, then gene expression was assessed using real-time PCR.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Introduction

Method & materials

Result and conclusion

PLOS ONE OPEN ACCESS Citation: Baziyar MA, Hosseini A, Jandel F (2024) The role of palbociclib on the alterations in CDKN2, CCNE1, E2F3, MDM2 expressions as target genes of miR-141 . PLoS ONE 19(8): e0306545 . [https://](https://)[ ](https://)[doi.org/10.1371/journal.pone.0306545](doi.org/10.1371/journal.pone.0306545) Editor: Sudhir Kumar Rai, University of Hawai’i at Manoa, UNITED STATES OF AMERICA Received: December 16, 2023 Accepted: June 18, 2024 Published: August 8, 2024 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal.pone.0306545](https://doi.org/10.1371/journal.pone.0306545) [Copyright:](Copyright:) © [2024](2024) Baziyar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: ll relevant data are within the manuscript and its Supporting Information files. Funding: The author(s) received no specific funding for this work. RESEARCH ARTICLE The role of palbociclib on the alterations in CDKN2, CCNE1, E2F3, MDM2 expressions as target genes of miR-141 Mohammad Ali Baziyar1, Arshad Hosseini1 *, Farinush Jandel2 1 Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran, 2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran * [hoseini.a@iums.ac.ir](hoseini.a@iums.ac.ir) Abstract Introduction According to WHO, Breast cancer is widely considered to be the first or second cause of cancer-related death almost universally. Cell cycle disruption, either in the form of uncontrolled expression of cyclins or because of the suspension in negative regulatory proteins (CDK inhibitors), was found to cause breast cancer. Palbociclib as specific CDK4/6 inhibitor is used for the treatment of ER+ metastatic cancers. In this study, we are looking to investigate the effect of palbociclib on breast cancer cells and evaluate the changes in the expression of some genes involved in the cell cycle as target genes of miR-141 after treatment with this drug. We used MCF7 as functional estrogen and non-invasive and MDA-MB-231 cell lines as triple-negative type of breast cancer and a model for more aggressive. Method & materials MCF7 and MDA-MB-231 cell lines were cultured in DMEM medium. After counting cells and measuring viability, Palbociclib was administered at varying doses using the IC50 obtained from MTT, with the treatment given at two time points of 24 and 72 hours. RNA was extracted from untreated and treated cells and RNAs were converted to cDNA in the end. Gene expression changes were investigated by real-time PCR. Data management and analysis were conducted using GraphPad Prism 5.01 software. Result and conclusion Among investigated genes, E2F3 gene was not significantly affected by Palbociclib in any of cell lines and time points. Besides, the expression of CCNE1 gene was significantly suppressed. It seems this drug was unable to reduce the expression of MDM2 gene significantly in triple negative (MDA-MB-231) cancer cells; however, a decrease was observed in luminal A (MCF-7) cells. CDKN2A and miR-141 genes expression increased significantly after treatment which can be aligned with palbociclib in proliferation inhibition. Competing interests: The authors have declared that no competing interests exist. 1. Introduction According to the World Health Organization (WHO), breast cancer is one of the leading causes of cancer-related deaths worldwide. It affects 2.3 million people each year, making it th

FAQs

What is the study investigating regarding palbociclib?

The study investigates the effect of palbociclib on breast cancer cells and evaluates changes in expression of genes involved in the cell cycle as target genes of miR-141.

Which breast cancer cell lines were used and how were they treated?

MCF7 and MDA-MB-231 cell lines were cultured in DMEM. Palbociclib was administered at varying doses based on IC50, with treatment at 24 and 72 hours.

What gene expression changes were reported after palbociclib treatment?

E2F3 was not significantly affected, CCNE1 expression was suppressed, and MDM2 decreased in luminal A (MCF7) but not significantly in triple-negative (MDA-MB-231) cells. CDKN2A and miR-141 expression increased significantly after treatment.

Sep 22, 2026

Upload by Asher